Targeted therapy with nanatinostat and valganciclovir in recurrent Epstein-Barr virus-positive lymphoid malignancies: a Phase 1b/2 study

By sjmartinez • August 3, 2023

Haverkos BM, Alpdogan O, Baiocchi RA, Brammer JE, Feldman T, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill SE, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. Targeted therapy with nanatinostat and valganciclovir in recurrent Epstein-Barr virus-positive lymphoid malignancies: a Phase 1b/2 study. Blood Adv. 2023 Aug 2:bloodadvances.2023010330. doi: 10.1182/bloodadvances.2023010330. Epub ahead of print. PMID: 37530631.

Tags: Hematology/Oncology, Publications

Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

Rodriguez GE, Zhao Y, Nishiga Y, Peprah F, Shen J, Abhiraman GC, Ogishi M, Zhang C, Saco J, Waghray D, Serasanambati M, Torres L, Simone[...]

Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases

Ni JR, Quirk M, Chmielowski B, Padia SA. Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases. Cardiovasc Intervent Radiol.[...]

Advancements in intratumoral therapies for liver tumors

Raman SS, Cutler NR, Sramek JJ, Hecht JR, Finn RS, Anand SR, Chiang J, Lu DS. Advancements in intratumoral therapies for liver tumors. Front Oncol.[...]